← All companies

Argenx

Healthcare & Life Sci

Company overview

Argenx develops antibody therapies for autoimmune diseases and cancer. Its main product, Efgartigimod, is marketed as VYVGART and treats generalized myasthenia gravis. It also develops Empasiprubart for severe IgM-driven autoimmune diseases.

Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier founded Argenx in 2008. The company trades on Euronext Brussels under ARGX and on NASDAQ. It has 1,863 employees and reported €4.2 billion in revenue for 2025. Historically, the median salary is ~$218,500. Argenx is an H-1B sponsor.

Industry
Healthcare & Life Sci
Headquarters
Ghent, Belgium

Filters

Create your account

Create an account to save jobs and track applications.